Becton, Dickinson and Company

NYSE:BDX

Medical - Instruments & Supplies

Healthcare
$216.08 +1.67%

+$2.36 today

Market cap
$58.86B
Beta
0.28
P/E (TTM)
35.5
EPS (TTM)
$4.06
Dividend yield
2.60%
52W Low $127.59High $187.35

Volume 1.32M

Average 2.76M

BDX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Becton, Dickinson and CompanyNYSE: BDX

Cost of Revenue · Q4 FY2026 · quarter ended Sep 2026

Cost of revenue declines year over year

Q4 FY2026 cost of revenue of $2.58B fell 16.5% year over year, behind the -10.1% change in trailing-twelve-month cost of revenue. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.

Context

  • Cost of revenue amounted to 52.6% of revenue in FY2026, down 1.9 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -16.5% toward the trailing-twelve-month pace of -10.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.58B-3.3% QoQ
Last fiscal yearSep 2026
$10.24B-14.0% YoY
LTMSep 2026
$10.72B-10.1% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.5%——
1 year-14.0%——
3-year CAGR-2.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2026
10.24B USD
Year-over-year change
-14.0%
4-year CAGR
-0.4%

Cost of Revenue vs competitors

How BDX compares with its peers on the latest reported figures

  • BDX's LTM Sep 2026 cost of revenue of $10.72B is the 3rd highest of the 11 companies compared; the peer median is $1.73B.
  • Its year-over-year change of -10.1% is the 9th highest of 11, against a peer median of +1.3%.
  • Cost of revenue amounts to 53.0% of revenue for BDX, versus a peer median of 45.8%.
BDX Competitors Peer median
Cost of Revenue for BDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABTAbbott LaboratoriesLTM Sep 2026$20.68B +2.5%-2.6%42.9%
MDTMedtronic plcLTM Jul 2026$12.51B +0.0%+5.9%33.3%
BDXBecton, Dickinson and CompanyLTM Sep 2026$10.72B -10.1%-2.9%53.0%
BAXBaxter International Inc.LTM Jun 2026$8.02B +13.9%+6.5%69.9%
SOLVSolventum CorporationLTM Jun 2026$3.77B -1.3%+4.1%45.3%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$2.1B +9.9%+4.1%63.2%
ICUIICU Medical, Inc.LTM Jun 2026$1.35B -11.4%-3.8%62.4%
TFXTeleflex IncorporatedLTM Jun 2026$1.2B -11.0%-11.5%46.2%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$815.11M +7.2%+7.2%50.6%
EMBCEmbecta Corp.LTM Mar 2026$390.7M -0.3%+4.2%37.5%
BLFSBioLife Solutions, Inc.LTM Mar 2026$36.03M +2.6%+5.1%36.1%
Peer median (excluding BDX) $1.73B+1.3%+4.1%45.8%

Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue18.87B19.37B20.18B21.84B19.46B
Cost of Revenue10.39B11.2B11.05B11.92B10.24B
Gross Profit8.48B8.17B9.13B9.92B9.21B
Gross Margin44.9%42.2%45.2%45.4%47.4%
Research & Development1.26B1.24B1.19B1.26B988M
Selling, General & Admin4.71B4.72B4.86B5.28B4.97B
Operating Expenses6.2B6.06B6.73B7.35B6.96B
Depreciation & Amortization2.23B2.29B2.29B2.46B2.24B
EBITDA4.41B4.4B4.82B4.96B4.61B
EBITDA Margin23.4%22.7%23.9%22.7%23.7%
Operating Income2.28B2.11B2.4B2.58B2.26B
Operating Margin12.1%10.9%11.9%11.8%11.6%
Interest Income16M49M163M38M27M
Interest Expense398M452M528M613M564M
Other Income / Expenses(499M)(449M)(392M)(696M)(451M)
Income Before Tax1.78B1.66B2.01B1.88B1.81B
Pre-Tax Margin9.4%8.6%9.9%8.6%9.3%
Income Tax Expense148M132M300M204M388M
Net Income1.78B1.48B1.71B1.68B1.15B
Net Margin9.4%7.7%8.4%7.7%5.9%
EPS (Basic)5.934.975.885.844.11
EPS (Diluted)5.884.945.865.834.09
Weighted Avg Shares285.01M286.28M289.76M286.61M278.49M
Weighted Avg Shares (Diluted)287.36M288.39M291.01M287.12M279.94M

Becton, Dickinson and Company

NYSE:BDX

Intrinsic Alpha fair value

Locked

Current Price

$216.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.